EBIT at other companies
Other financials
Where this comes from
Calculated from Alnylam Pharmaceuticals’s reported figures.
The official record: Alnylam Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alnylam Pharmaceuticals's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alnylam Pharmaceuticals's EBIT?
- Alnylam Pharmaceuticals (ALNY) reported EBIT of $268.64M in Q1 2026.
- How has Alnylam Pharmaceuticals's EBIT changed year-over-year?
- Alnylam Pharmaceuticals's EBIT increased by 1386.1% year-over-year, from $18.08M to $268.64M.
- What is the long-term trend for Alnylam Pharmaceuticals's EBIT?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's EBIT has grown at a -8.3% compound annual growth rate (CAGR), from -$708.65M to $501.58M.
- What does EBIT mean?
- Profit before interest and taxes — the business's core earning power.
- How do you interpret EBIT?
- Higher is better. Because it adds back interest, EBIT compares earning power across firms with very different debt loads — the base for interest coverage and the EV/EBIT multiple. For filers reporting operating income it equals that line, excluding non-operating swings.
- How does EBIT compare across companies?
- Comparable across companies regardless of leverage or tax domicile; the standard 'earning power' line for cross-company analysis. Least meaningful for banks and insurers.